NEURIMMUNE HOLDING
Neurimmune is a biopharmaceutical company dedicated to the development of immunotherapeutics for the treatment and prevention of human disorders with high unmet medical needs. With its unique Reverse Translational Medicine™ platform, Neurimmune creates recombinant human-derived monoclonal antibodies with biophysical characteristics closely resembling those occurring in healthy elderly. These antibodies display unique properties such as target selectivity, superior pharmacodynamics and low imm... unogenicity, resulting in superior risk profiles and excellent efficacy. Neurimmune’s pipeline comprises programs for a broad variety of disease related targets and specific target conformations. These include misfolded, oligomeric, fibrillar or post-translationally modified forms of disease-associated proteins as well as physiological conformations involved in major disease pathways.
NEURIMMUNE HOLDING
Industry:
Biotechnology Information Technology Pharmaceutical
Founded:
2006-01-01
Address:
Schlieren, Zurich, Switzerland
Country:
Switzerland
Website Url:
http://www.neurimmune.com
Total Employee:
51+
Status:
Active
Contact:
41 44 755 46 46
Total Funding:
150 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager Domain Not Resolving Mobile Non Scaleable Content
Similar Organizations
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Aratana Therapeutics
Aratana Therapeutics develops innovative therapies for the animal health industry.
BioSilta
BioSilta Ltd, a developer of advanced microbial growth systems,
Immutep
Immutep is a biopharmaceutical company developing immunotherapeutics in oncology.
PBS Biotech
PBS Biotech is produces the easiest to use and most technologically-advanced bioreactors for the pharmaceutical industry.
Sirnaomics
Sirnaomics is a biopharmaceutical company developing therapeutics for critical human diseases by using RNA interference technology.
Sutro Biopharma
Sutro Biopharma develops protein therapeutics by using OCFS protein synthesis technology.
Current Advisors List
Board_member
2015-01-01
Current Employees Featured
Michael Salzmann COO & General Manager @ Neurimmune Holding
COO & General Manager
Roger M Nitsch President & CEO @ Neurimmune Holding
President & CEO
Dirk Schimkat CFO @ Neurimmune Holding
CFO
Jan Grimm CSO @ Neurimmune Holding
CSO
2007-01-01
Founder
Investors List
Biogen Idec
Biogen Idec investment in Venture Round - Neurimmune Holding
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2019-03-04 | NovaGo Therapeutics | Neurimmune Holding investment in Series A - NovaGo Therapeutics | 10 M CHF |
| 2016-12-08 | AL-S Pharma | Neurimmune Holding investment in Seed Round - AL-S Pharma | N/A |
Official Site Inspections
http://www.neurimmune.com Semrush global rank: 1.06 M Semrush visits lastest month: 31.62 K
- Host name: cloudone.goldinteractive.ch
- IP address: 46.231.204.136
- Location: Lengnau Switzerland
- Latitude: 47.1838
- Longitude: 7.3737
- Timezone: Europe/Zurich
- Postal: 2543
More informations about "Neurimmune Holding"
Neurimmune Holding - Crunchbase Company Profile & Funding
Neurimmune is a biopharmaceutical company dedicated to the development of immunotherapeutics for the treatment and prevention of human disorders with high unmet …See details»
Neurimmune AG - LinkedIn
Neurimmune AG | 4,109 followers on LinkedIn. Translating the library of life into transformative therapeutics. | Neurimmune is a biopharmaceutical company translating human immune …See details»
Board of Directors – Neurimmune
He co-founded Neurimmune in 2006 and acts as Chief Medical Officer (CMO). Previously, Christoph served as Vice-President Medicine and Science on the executive board of the …See details»
Neurimmune Therapeutics AG - VentureRadar
"Neurimmune is a biopharmaceutical company translating human immune memory into transformative therapeutics. Neurimmune’s pipeline comprises drug candidates for …See details»
Neurimmune AG – Swiss Biotech
Neurimmune is a biopharmaceutical company translating human immune memory into transformative antibody therapeutics. Neurimmune develops drug candidates for CNS and …See details»
Executive Committee – Neurimmune
Neurimmune's Executive Committee has a proven track record in preclinical research, clinical product development and life science industry partnering.See details»
Neurimmune Holding AG - Drug pipelines, Patents, Clinical trials
May 7, 2025 Explore Neurimmune Holding AG with its drug pipeline, therapeutic area, technology platform, 2 clinical trials, 47 news, Disease Domain:Nervous System Diseases, …See details»
About us – Neurimmune
Neurimmune Subone AG is a biopharmaceutical company involved in the discovery and development of aducanumab.See details»
Our Business – Neurimmune
The company's entrepreneurial business model permits independent decision making similar to a family-run enterprise. It relies on strategic collaborations with selected industry partners for …See details»
Company History – Neurimmune
2006 Founded on 14th of November by Roger Nitsch, Christoph Hock and Jan Grimm as a University of Zurich spin-off company after encouragement and advice by serial biotech …See details»
Home – Neurimmune
Neurimmune is a biopharmaceutical company translating human immune memory into antibody therapeutics. Neurimmune’s pipeline comprises drug candidates for Alzheimer’s disease, …See details»
About Neurimmune – Neurimmune
Neurimmune is a biopharmaceutical company translating human immune memory into transformative therapeutics. Neurimmune’s pipeline comprises drug candidates for …See details»
Biogen Idec and Neurimmune Announce Agreement on Three ...
WESTON, Mass. & ZURICH-- (BUSINESS WIRE)-- Biogen Idec (NASDAQ: BIIB) and Neurimmune Holding AG today announced that Biogen Idec has acquired a subsidiary of …See details»
Neurimmune to regain global rights to brain amyloid depleter for …
Jan 31, 2024 Neurimmune licensed its antibody aducanumab for the treatment and prevention of Alzheimer’s disease to Biogen in 2007 and will hold global rights to the program following …See details»
Neurimmune Holding AG (Neurimmune Holding AG) - 药物管线_ …
May 7, 2025 Neurimmune today announced that the translational PK/PD model relating to the human antibody ALXN2220 (formerly NI006) have been published in the current issue of …See details»
Neurimmune AG (Neurimmune AG) - 药物管线_专利_临床试验_投 …
Mar 7, 2025 Neurimmune announced today that a Donald L. Price Memorial Lecture will be held at the 18th International Conference on Alzheimer’s and Parkinson’s Diseases and related …See details»
AstraZeneca goes bigger in amyloidosis with Neurimmune deal
2 days ago AstraZeneca has clearly made the rare disease transthyretin amyloidosis (ATTR) a key component of its rare disease pipeline, licensing a second drug candidate in the space of …See details»
Biogen Files Suit Against Neurimmune Over Rights to Bispecific …
2 days ago Biogen seeks a declaratory judgment that the Agreement gives Neurimmune no rights, ownership, license, or other interest to the bispecific antibody at issue or Biogen’s …See details»
Pipeline – Neurimmune
NI101SQ is a novel subcutaneous version of aducanumab, formulated for autoinjector self-administration.It is a human monoclonal antibody against beta amyloid in development for the …See details»
Biogen Files Suit Against Neurimmune Over Rights to Bispecific …
21 hours ago Biogen seeks a declaratory judgment that the Agreement gives Neurimmune no rights, ownership, license, or other interest to the bispecific antibody at issue or Biogen’s …See details»